Vectura, the Chippenham-based drug development firm, has extended further extended its global network of blue-chip collaborators by signing a licence agreement with a major US biotech company. Vectura will exclusively develop anti-inflammatory therapies for the treatment of asthma/ chronic obstructive pulmonary disease (COPD) for Janssen Biotech under the agreement. Vectura said the collaboration would...